Mallinckrodt updates spin-off plans; FDA expands Vraylar approval for Allergan; Juvenescence spawns Souvien Therapeutics
→ UK-based biopharmaceutical company Mallinckrodt $MNK — the maker of the controversial drug Acthar — has updated its plans for its new spin-off company, first announced last year. The new plan is to divide the company into two independent publicly traded companies: one encapsulating the specialty generics/active pharmaceutical ingredients side of the business, while the other will encompass the specialty branded pharmaceuticals business.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.